These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24659339)

  • 1. Synergistic effects of eukaryotic coexpression plasmid carrying LKB1 and FUS1 genes on lung cancer in vitro and in vivo.
    Li L; Yu C; Ren J; Ye S; Ou W; Wang Y; Yang W; Zhong G; Chen X; Shi H; Su X; Chen L; Zhu W
    J Cancer Res Clin Oncol; 2014 Jun; 140(6):895-907. PubMed ID: 24659339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cationic liposome mediated delivery of FUS1 and hIL-12 coexpression plasmid demonstrates enhanced activity against human lung cancer.
    Ren J; Yu C; Wu S; Peng F; Jiang Q; Zhang X; Zhong G; Shi H; Chen X; Su X; Luo X; Zhu W; Wei Y
    Curr Cancer Drug Targets; 2014; 14(2):167-80. PubMed ID: 24410728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced antitumor effect of cisplatin in human NSCLC cells by tumor suppressor LKB1.
    Ou W; Ye S; Yang W; Wang Y; Ma Q; Yu C; Shi H; Yuan Z; Zhong G; Ren J; Zhu W; Wei Y
    Cancer Gene Ther; 2012 Jul; 19(7):489-98. PubMed ID: 22576699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells.
    Deng WG; Kawashima H; Wu G; Jayachandran G; Xu K; Minna JD; Roth JA; Ji L
    Cancer Res; 2007 Jan; 67(2):709-17. PubMed ID: 17234782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effects of eukaryotic co-expression plasmid-based STAT3-specific siRNA and LKB1 on ovarian cancer in vitro and in vivo.
    Pan Y; Zhang L; Zhang X; Liu R
    Oncol Rep; 2015 Feb; 33(2):774-82. PubMed ID: 25420630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner.
    Meng J; Majidi M; Fang B; Ji L; Bekele BN; Minna JD; Roth JA
    PLoS One; 2013; 8(10):e77067. PubMed ID: 24146957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo.
    Ito I; Ji L; Tanaka F; Saito Y; Gopalan B; Branch CD; Xu K; Atkinson EN; Bekele BN; Stephens LC; Minna JD; Roth JA; Ramesh R
    Cancer Gene Ther; 2004 Nov; 11(11):733-9. PubMed ID: 15486560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1.
    Deng WG; Wu G; Ueda K; Xu K; Roth JA; Ji L
    Cancer Gene Ther; 2008 Jan; 15(1):29-39. PubMed ID: 17828283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
    Memmott RM; Gills JJ; Hollingshead M; Powers MC; Chen Z; Kemp B; Kozikowski A; Dennis PA
    Cancer Res; 2008 Jan; 68(2):580-8. PubMed ID: 18199555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additive effects of eukaryotic co‑expression plasmid carrying GRIM‑19 and LKB1 genes on breast cancer in vitro and in vivo.
    Zhang W; Shao Y; Du Y; Geng W; Jiang T; Liu H; Zhang D
    Mol Med Rep; 2015 Nov; 12(5):7665-72. PubMed ID: 26458553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoplasmic liver kinase B1 promotes the growth of human lung adenocarcinoma by enhancing autophagy.
    Liu M; Jiang L; Fu X; Wang W; Ma J; Tian T; Nan K; Liang X
    Cancer Sci; 2018 Oct; 109(10):3055-3067. PubMed ID: 30033530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
    Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
    J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis.
    Nagalingam A; Arbiser JL; Bonner MY; Saxena NK; Sharma D
    Breast Cancer Res; 2012 Feb; 14(1):R35. PubMed ID: 22353783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CO suppresses prostate cancer cell growth by directly targeting LKB1/AMPK/mTOR pathway in vitro and in vivo.
    Yan Y; Du C; Li G; Chen L; Yan Y; Chen G; Hu W; Chang L
    Urol Oncol; 2018 Jun; 36(6):312.e1-312.e8. PubMed ID: 29566977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
    Liu Y; Li Y; Wang X; Liu F; Gao P; Quinn MM; Li F; Merlino AA; Benes C; Liu Q; Gray NS; Wong KK
    Cancer Res; 2017 Sep; 77(18):5068-5076. PubMed ID: 28754670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.
    Whang YM; Park SI; Trenary IA; Egnatchik RA; Fessel JP; Kaufman JM; Carbone DP; Young JD
    Oncogene; 2016 Feb; 35(7):856-66. PubMed ID: 26119936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Construction and identification of eukaryotic co-expression plasmid carrying FUS1 and recombinant human IL-12 genes and its effection on apoptosis of A549 cells].
    Zhang DM; Yang HS; Zhu W; Feng ZH; Deng HX; Wei YQ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 40(4):569-74. PubMed ID: 19764546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
    Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
    Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.
    Della Corte CM; Ciaramella V; Di Mauro C; Castellone MD; Papaccio F; Fasano M; Sasso FC; Martinelli E; Troiani T; De Vita F; Orditura M; Bianco R; Ciardiello F; Morgillo F
    Oncotarget; 2016 Jan; 7(4):4265-78. PubMed ID: 26673006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient inhibition of lung cancer in murine model by plasmid-encoding VEGF short hairpin RNA in combination with low-dose DDP.
    Ma YP; Yang Y; Zhang S; Chen X; Zhang N; Wang W; Cao ZX; Jiang Y; Zhao X; Wei YQ; Deng HX
    J Exp Clin Cancer Res; 2010 May; 29(1):56. PubMed ID: 20497582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.